Mudvari, AnishPrasad, PravinPokharel, AkriteeThapaliya, SabinMaharjan, BindiraKhadka, RebantaLamsal, Arun BatsaGhimire, RanjeetBista, Apeksha2025-11-032025-11-032025https://hdl.handle.net/20.500.14572/3018Anish Mudvari Maharajgunj Medical Campus, Tribhuvan University Author https://orcid.org/0000-0002-0509-2982 Pravin Prasad Author Akritee Pokharel Author Sabin Thapaliya Author Bindira Maharjan Author Rebanta Khadka Author Arun Batsa Lamsal Author Ranjeet Ghimire Author Apeksha Bista AuthorABSTRACT: Introduction The COVID-19 pandemic poses a major health threat with no standardized treatments for SARS-CoV-2. This study evaluates pharmacotherapy trends in COVID-19 patients during the second wave at a tertiary care facility. Methods A retrospective, observational, cross-sectional study was conducted in a tertiary care centre, utilising patient data from April 2021 to July 2021. The sample included 310 patients admitted with a confirmed diagnosis of COVID-19. Patients were classified based on oxygen requirement levels, and data were analysed using descriptive statistics. Results Of the 310 patients, 59% were male and 41% female, with a mean age of 53.37 ± 17.01 years. The average hospital stay was 10 ± 7.15 days. Most patients (66.8%) required supplemental oxygen, and 7.4% required mechanical ventilation. The majority received antibacterial therapy (307, 99.03%), with ceftriaxone being the most commonly prescribed antibiotic (73.22%). Remdesivir was the predominant antiviral, and dexamethasone was used in 88.39% of patients. Conclusion Antibiotic use was extensive among hospitalised COVID-19 patients, with ceftriaxone being the most common. Antiviral use was less frequent, with Remdesivir being the preferred choice. Dexamethasone played a crucial role in managing severe cases.en-USCOVID-19pharmacotherapyantibacterialremdesivirdexamethasoneNepalhospitalized patientsArticle